DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kyung-Sun Hwang | - |
dc.contributor.author | Won-Kyung Cho | - |
dc.contributor.author | JinSang Yoo | - |
dc.contributor.author | H J Yun | - |
dc.contributor.author | S Kim | - |
dc.contributor.author | Dong Soo Im | - |
dc.date.accessioned | 2017-04-19T09:02:52Z | - |
dc.date.available | 2017-04-19T09:02:52Z | - |
dc.date.issued | 2005 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | 10.1186/1471-2407-5-51 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/6965 | - |
dc.description.abstract | Background: Therapeutic gene transfer affords a clinically feasible and safe approach to cancer treatment but a more effective modality is needed to improve clinical outcomes. Combined transfer of therapeutic genes with different modes of actions may be a means to this end. Interleukin-12 (IL-12), a heterodimeric immunoregulatory cytokine composed of covalently linked p35 and p40 subunits, has antitumor activity in animal models. The enzyme/prodrug strategy using cytosine deaminase (CD) and 5-fluorocytosine (5-FC) has been used for cancer gene therapy. We have evaluated the antitumor effect of combining IL-12 with CD gene transfer in mice bearing renal cell carcinoma (Renca) tumors. Methods: Adenoviral vectors were constructed encoding one or both subunits of murine IL-12 (Ad.p35, Ad.p40 and Ad.IL-12) or cytosine deaminase (Ad.CD). The functionality of the IL-12 or CD gene products expressed from these vectors was validated by splenic interferon (IFN)-γ production or viability assays in cultured cells. Ad.p35 plus Ad.p40, or Ad.IL-12, with or without Ad.CD, were administered (single-dose) intratumorally to Renca tumor-bearing mice. The animals injected with Ad.CD also received 5-FC intraperitoneally. The antitumor effects were then evaluated by measuring tumor regression, mean animal survival time, splenic natural killer (NK) cell activity and IFN-γ production. Results: The inhibition of tumor growth in mice treated with Ad.p35 plus Ad.p40 and Ad.CD, followed by injection of 5-FC, was significantly greater than that in mice treated with Ad.CD/5-FC, a mixture of Ad.p35 plus Ad.p40, or Ad.GFP (control). The combined gene transfer increased splenic NK cell activity and IFN-γ production by splenocytes. Ad.CD/5-FC treatment significantly increased the antitumor effect of Ad.IL-12 in terms of tumor growth inhibition and mean animal survival time. Conclusions: The results suggest that adenovirus-mediated IL-12 gene transfer combined with Ad.CD followed by 5-FC treatment may be useful for treating cancers. | - |
dc.publisher | Springer-BMC | - |
dc.title | Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice | - |
dc.title.alternative | Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice | - |
dc.type | Article | - |
dc.citation.title | BMC Cancer | - |
dc.citation.number | 0 | - |
dc.citation.endPage | 85 | - |
dc.citation.startPage | 51 | - |
dc.citation.volume | 5 | - |
dc.contributor.affiliatedAuthor | Kyung-Sun Hwang | - |
dc.contributor.affiliatedAuthor | Won-Kyung Cho | - |
dc.contributor.affiliatedAuthor | JinSang Yoo | - |
dc.contributor.affiliatedAuthor | Dong Soo Im | - |
dc.contributor.alternativeName | 황경선 | - |
dc.contributor.alternativeName | 조원경 | - |
dc.contributor.alternativeName | 유진상 | - |
dc.contributor.alternativeName | 윤환중 | - |
dc.contributor.alternativeName | 김삼용 | - |
dc.contributor.alternativeName | 임동수 | - |
dc.identifier.bibliographicCitation | BMC Cancer, vol. 5, pp. 51-85 | - |
dc.identifier.doi | 10.1186/1471-2407-5-51 | - |
dc.description.journalClass | Y | - |
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.